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Objectives The purpose of this study was to examine the association between human papillomavirus (HPV) and cardiovas-
cular disease (CVD) among U.S. women.
Background Oncogenic proteins derived from tumor-associated HPV induce the degradation of tumor suppressor protein p53.
Inactivation of p53 is associated with accelerated atherosclerotic process. However, the association between
HPV infection with CVD remains unclear.
Methods Data were from 2,450 women (age 20 to 59 years) in the National Health and Nutrition Examination Survey,
2003 to 2006. Self-collected vaginal swab specimens were sent for HPV DNA analysis by L1 consensus polymer-
ase chain reaction followed by type-specific hybridization. CVD was ascertained by self-reported diagnosis of
myocardial infarction or stroke.
Results A total of 60 females (39 women were HPV DNA positive, whereas 21 were negative) had coronary artery dis-
ease. Presence of vaginal HPV DNA was associated with CVD. Odds ratio (OR) of CVD comparing women with
presence of vaginal HPV DNA to those without was 2.30 (95% confidence interval [CI]: 1.27 to 4.16) after con-
trolling for demographics, health/sex behaviors, medical comorbidities, cardiovascular risk factors, and manage-
ment. At the same level of adjustment, OR of CVD comparing women with cancer-associated HPV types to those
with negative HPV was 2.86 (95% CI: 1.43 to 5.70).
Conclusions HPV infection, especially cancer-associated oncogenic types, is associated with CVD among women. (J Am Coll
Cardiol 2011;58:2001–6) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.038Extensive research indicates that cigarette smoking, diabe-
tes, dyslipidemia, and hypertension, collectively labeled as
conventional risk factors, are important contributors to
cardiovascular disease (CVD) (1–3) and that treatment of
these risk factors is associated with reduced risk of future
cardiovascular events (4). However, nearly 20% of individ-
uals with CVD do not have any of the conventional risk
factors (5), indicating that other “nontraditional” factors
may play an essential role in the development of CVD.
Human papillomavirus (HPV) infection is one of the
most common sexually transmitted infections in the United
States. A recent study from the National Health and
Nutrition Examination Survey (NHANES) reported an
overall HPV prevalence of 26.8% (6). HPVs, especially
“oncogenic” or cancer-associated types, are implicated as a
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accepted July 5, 2011.causative agent of anogenital cancers (7,8). The viral onco-
proteins bind to cellular tumor-suppressor protein p53 and
therefore induce the degradation of p53 through the ubiq-
uitin pathway (9,10). p53 is essential in regulating the
process of atherosclerosis (11). Absence of p53 has been
shown to accelerate atherosclerosis in vivo (12), and human
See page 2007
study also demonstrated an association between p53 inacti-
vation and post-atherectomy coronary restenosis (13). Al-
though the role of HPV is well known in the development
of anogenital cancers, the potential atherosclerotic outcome
of HPV infection (through interaction between HPV on-
coproteins and p53) is largely unknown and has not been
investigated. We hypothesized that HPV infection is asso-
ciated with CVD among women. The objective of this study
was to test the hypothesis by analyzing data from the
NHANES 2003 to 2006.
Methods
Data source and study sample. The data come from the
NHANES 2003 to 2006, a population-based cross-sectional
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tion on the health and nutrition of
the U.S. civilian noninstitutional-
ized population.
Of 3,467 females aged 20 to
59 years who were interviewed
at home for the 2003 to 2006
cycles, 3,330 were examined in
a mobile examination center.
Among them, 2,829 females
(85.0%) submitted cervicovaginal
swab specimens, whereas 501 fe-
males did not. Of the 2,829 fe-
males who submitted cervicova-
ginal swab specimens, 42 females
submitted an inadequate swab specimen. A total of 543
females (16.3%) were considered nonresponders because
they either submitted an inadequate swab specimen (n 
42) or they did not submit a swab specimen (n  501).
Compared with responders, nonresponders were signifi-
cantly more likely to be of all other race (race/ethnicity other
than Hispanic, black, or white) (8.8% vs. 4.4%, p  0.001),
and to be younger (age 34.0 years vs. 37.7 years, p 0.001).
Among the 2,787 women with adequate specimens, we
further excluded 337 participants with missing covariates in
laboratory measurements or health behavior questionnaire,
leaving 2,450 women as the final analytic sample.
HPV DNA examination and genotyping. Self-collected
vaginal swabs were evaluated for HPV infection. Vaginal
specimens were processed, stored, and then shipped to
Atlanta, Georgia, for analysis. DNA was extracted using
modifications of QIAmp Mini Kit protocol (Qiagen, Va-
lencia, California) within 1 month of sample collection, and
HPV detection and genotyping were conducted as described
elsewhere (6). In brief, HPV detection and typing were
performed by using the Roche Linear Array Assay (Roche
Molecular Systems Inc, Pleasanton, California). The assay
used HPV L1 consensus polymerase chain reaction (PCR)
with biotinylated PGMY09/11 primer sets and  -globin as
an internal control for sample amplification. The primer mix
amplifies essentially all HPV types found in the genital
tract. After amplification, the samples were then typed by
hybridization to the typing strips followed by colorimetric
detection. The strip was a linear array of probes specific for
37 HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45,
51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70,
71, 72, 73, 81, 82, 83, 84, IS39, and 89) and for positive
-globin as well. Types were read by comparing the reaction
pattern to the typing template. Samples negative for both
-globin and HPV were considered inadequate for inter-
pretation (n  42, 1.48%) and were omitted from further
analysis. HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, and 68 were defined as oncogenic or cancer-
associated HPV types (14).
Cardiovascular disease. Cardiovascular disease (CVD)
Abbreviations
and Acronyms
BP  blood pressure
CI  confidence interval
CVD  cardiovascular
disease
HDL  high-density
lipoprotein
HPV  human
papillomavirus
OR  odds ratio
STD  sexually transmitted
diseasewas ascertained by self-reported questionnaires: “Has adoctor or other health professional ever told you that you
had a heart attack (also called myocardial infarction)?” or
“Has a doctor or other health professional ever told you that
you had a stroke?” Answering yes to either question was
coded positive for CVD.
Assessment of demographics and clinical factors. Age,
race, sex behavior, and alcohol consumption were obtained
by self-report. Sex was defined as vaginal, oral, or anal sex.
Body mass index, calculated as weight in kilograms divided
by the square of height in meters, was categorized according
to the National Institutes of Health obesity standards:
18.5  underweight, 18.5 to 24.9  normal weight, 25.0
to 29.9  overweight, and 30  obese (15). Using their
serum cotinine concentrations, we classified smoking status
of participants into 4 groups: nonsmoker (14 ng/ml), light
smoker (14 to 99 ng/ml), moderate smoker (100 to 199
ng/ml), and heavy smoker (200 ng/ml) (16). Comorbidi-
ties, including lung disease (defined as asthma, emphysema,
or chronic bronchitis), liver disease, thyroid disease, sexually
transmitted diseases (STDs), or cancer (including cervical
cancer or all other cancer), use of cholesterol-lowering
medications, and use of antihypertensive medications, were
ascertained by self-report. Diabetes was defined by self-
report of a physician’s diagnosis, the presence of a fasting
(fasting 6 h) plasma glucose level 126 mg/dl or a
nonfasting (fasting 6 h) glucose level  200 mg/dl,
hemoglobin A1C 6.5% (5), or the use of diabetic medica-
tions. Hypertension was defined as mean systolic blood
pressure (BP) 140 mm Hg, mean diastolic BP 90 mm
Hg, physician diagnosis, or use of antihypertensive medica-
tions. Mean BP was composed of up to 4 readings on 2
separate occasions. Waist circumference was measured at
the iliac crest to the nearest 0.1 cm. Serum triglycerides,
high-density lipoprotein (HDL) cholesterol, C-reactive
protein, serum creatinine, urinary albumin, urinary creati-
nine were analyzed by laboratory methods reported else-
where (17,18). Urinary albumin-to-creatinine ratio (in mil-
ligrams per gram) was calculated accordingly. Estimated
glomerular filtration rate was calculated by using the Mod-
ification of Diet in Renal Disease study equation (19).
Analysis. Demographic and clinical characteristics of the
study population were presented according to HPV geno-
types, namely, cancer-associated HPV types (n  573),
other HPV types (n  568), or negative HPV (n  1,309).
Chi-square test or t-test was used to determine differences
between groups. Association of metabolic risks with HPV
genotypes was examined using multiple regression. To
consider various metabolic risk factors as a whole, we also
calculated the metabolic z-score. The score was derived by
converting each component of the metabolic risk factors,
namely blood pressure, waist circumference, levels of glu-
cose, triglyceride level, and HDL level, into a z-score based
on means of the study population (20). The metabolic
z-score was calculated by summation of the former 4
z-scores minus the HDL z-score. Multiple logistic regres-
sion analysis was used to examine the association of HPV
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HPV DNA were the reference category. We used an
extended-model approach for covariate adjustment: Model
1  age and race; Model 2  Model 1  health behaviors
smoking and alcohol consumption) and sex behavior;
odel 3Model 2 medical comorbidities (lung disease,
iver disease, thyroid disease, estimated glomerular filtration,
TDs, history of cervical cancer, history of all other cancer);
odel 4  Model 3  cardiovascular risk factors and
management (hypertension, diabetes mellitus, waist circumfer-
ence, triglycerides, HDL cholesterol, log-transformed levels of
C-reactive protein and urinary albumin-to-creatinine ratio, use
of antihypertensive agents or cholesterol-lowering medica-
tions); and Model 5  Model 3  metabolic z-score, use of
ntihypertensive agents or cholesterol-lowering medications.
NHANES weights were not adjusted in the analyses
ecause they apply to prevalence estimates of the entire
opulation, and our study aimed to evaluate associations in
certain subset of women with valid data of HPV DNA
xamination and genotyping. Data analyses were performed
sing STATA 10.0 software (STATA Corporation, Col-
ege Station, Texas).
esults
omen in this study were generally young, with a mean age
f 37.9 years. The prevalence of CVD was low, with a total
f 60 women (2.5%) reported having either myocardial
Characteristics of Study Participants According to HPV GenotypesTable 1 Characteristics of Study Participants According to HPV
HP
Variables
Cancer-Associated HPV Types
(n  573)
Age group
20–29 yrs 218 (38.0)
30–45 yrs 209 (36.5)
46–59 yrs 146 (25.5)
Race
Mexican American 113 (19.7)
Other Hispanics 18 (3.2)
Non-Hispanic white 254 (44.3)
Non-Hispanic black 166 (29.0)
All others 22 (3.8)
12 alcoholic drinks in the last yr 382 (66.7)
Nonsmoker 395 (68.9)
Ever had sex behavior 548 (95.6)
Cardiovascular disease 20 (3.5)
Hypertension 124 (21.6)
Diabetes mellitus 38 (6.6)
Lung disease 119 (20.8)
Liver disease 15 (2.6)
Thyroid disease 68 (11.9)
Cancer 33 (5.8)
Cervical cancer 12 (2.1)
All other cancer 21 (3.7)
Sexually transmitted disease 84 (14.7)Cancer-associated human papillomavirus (HPV) types  HPV types 16, 18, 31, 33, 35, 39, 45 51, 52, 56nfarction or stroke. Among study participants (N 2,450),
,141 women (46.6%) were positive for HPV DNA. Five
undred seventy-three women (23.2% of study population)
ad cancer-associated HPV types. Characteristics of the
tudy sample by HPV genotypes were summarized (Table 1).
omen without HPV infection tended to be nonsmokers
nd to drink less, whereas women with cancer-associated
PV types were more likely to be younger and tended to
ave higher prevalence of CVD. There was no difference in
revalence of diabetes mellitus, lung disease, liver disease,
hyroid disease, and cancer between groups.
ssociation between HPV and various metabolic risks.
arious metabolic risks, including systolic blood pressure,
iastolic blood pressure, abdominal circumference, levels of
lood glucose, triglyceride, and HDL cholesterol, and a
omposite metabolic z-score were compared in 3 different
roups: cancer-associated HPV types, other HPV types, and
egative HPV. We did not find any association between
PV and various metabolic risks. Adjusted means of
arious metabolic risks were comparable across 3 different
roups after controlling for age, race, and health/sex behav-
ors (Table 2).
ssociation between HPV and cardiovascular disease.
he results of multiple logistic regression analysis for the
ssociation between HPV and CVD are summarized in
able 2. After adjusting for age and race, presence of vaginal
PV DNA was associated with CVD. Odds ratio (OR) of
NES 2003 to 2006 (N  2,450)otypes, NHANES 2003 to 2006 (N  2,450)
otype
ther HPV Types
(n  568)
Negative
(n  1,309)
Total
(N  2,450) p Value
0.001
141 (24.8) 355 (27.1) 714 (29.2)
255 (44.9) 546 (41.7) 1,010 (41.2)
172 (30.3) 408 (31.2) 726 (29.6)
0.001
114 (20.1) 279 (21.3) 506 (20.7)
22 (3.9) 49 (3.7) 89 (3.6)
242 (42.6) 691 (52.8) 1,187 (48.4)
170 (29.9) 222 (17.0) 558 (22.8)
20 (3.5) 68 (5.2) 1,10 (4.5)
363 (63.9) 785 (60.0) 1,530 (62.5) 0.016
415 (73.1) 1,078 (82.4) 1,888 (77.1) 0.001
540 (95.1) 1,219 (93.1) 2,307 (94.2) 0.058
19 (3.35) 21 (1.6) 60 (2.5) 0.015
161 (28.4) 289 (22.1) 574 (23.5) 0.007
42 (7.4) 95 (7.3) 175 (7.1) 0.858
124 (21.8) 240 (18.3) 483 (19.7) 0.167
18 (3.2) 30 (2.3) 63 (2.6) 0.543
60 (10.6) 154 (11.8) 282 (11.5) 0.721
28 (4.9) 68 (5.2) 129 (5.3) 0.810
10 (1.8) 22 (1.7) 44 (1.8) 0.822
18 (3.2) 46 (3.5) 85 (3.5) 0.893
86 (15.1) 107 (8.2) 277 (11.3) 0.001, NHAGen
V Gen
O, 58, 59, and 68.
*The 
d sted for
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DNA to those without was 2.46 (95% confidence interval
[CI]: 1.42 to 4.27). Further covariates adjustment, including
health/sex behaviors, medical comorbidities, composite
metabolic z-score, and cardiovascular risk factors and man-
agement (Models 2 to 5), only mildly attenuated the
association between HPV and CVD (Table 3). We then
examined the relation of HPV genotypes with CVD and
found that cancer-associated HPV types were specifically
associated with either myocardial infarction or stroke. After
controlling for demographics, health/sex behaviors, med-
ical comorbidities, and cardiovascular risk factors and man-
agement, the OR of CVD comparing women with cancer-
associated HPV types to those with negative HPV was 2.86
(95% CI: 1.43 to 5.70). Presence of other types of HPV
DNA was not associated with CVD in the multivariate
Models 2 to 5. Interactive effects between age and HPV
genotypes on CVD were tested across Models 1 to 5, and no
interaction was identified.
Discussion
Among U.S. women age 20 to 59 years, HPV infection is
likely associated with myocardial infarction or stroke.
Cancer-associated HPV genotypes, but not other HPV
genotypes, are selectively related to presence of CVD. The
association between HPV and CVD still perseveres after
adjustment for health/sex behaviors, medical conditions,
and cardiovascular risk burden and management, indicating
that conventional risk factors cannot fully explain the
Relation of HPV to Various Metabolic RisksTable 2 Relation of HPV to Various Metabolic Risks
Metabolic Risks HPV Genotypes
Systolic blood pressure, mm Hg HPV negative
Other HPV types
Cancer-associated HPV types
Diastolic blood pressure, mm Hg HPV negative
Other HPV types
Cancer-associated HPV types
Abdominal circumference, cm HPV negative
Other HPV types
Cancer-associated HPV types
Blood glucose, mg/dl HPV negative
Other HPV types
Cancer-associated HPV types
Triglyceride, mg/dl HPV negative
Other HPV types
Cancer-associated HPV types
HDL cholesterol, mg/dl HPV negative
Other HPV types
Cancer-associated HPV types
Metabolic z-score HPV negative
Other HPV types
Cancer-associated HPV types
Cancer-associated HPV types  HPV types 16, 18, 31, 33, 35, 39, 45 51, 52, 56, 58, 59, and 68.
ifferent categories of HPV (human papillomavirus) genotypes to those with negative HPV. †Adjurelation of HPV to CVD and that presence of HPVinfection, especially cancer-associated genotypes, is a strong
and independent correlate for CVD. To the best of our
knowledge, there is no previous report on the association
between HPV and CVD. This is the first report to
investigate the association between HPV infection and
CVD by using a geographically dispersed and ethnically
diverse representative sample of community-dwelling
women living in the United States. Potential confounders
were also comprehensively considered.
The possible mechanistic explanations behind the newly
found association are intriguing. The products of 2 tumor
suppressor genes, p53 and retinoblastoma protein (pRb),
might be involved in the mechanisms for the association
between HPV and CVD. HPV oncoproteins interact with
and inactivate both p53 and the pRb. In animal studies
using different models, knockout of p53 gene (12), trans-
planting mice with bone marrow from p53 knockout mice
(21), and macrophage-specific loss of p53 function (22)
were all associated with considerably increased atheroscle-
rotic lesion size with the presence of more lesion necrosis
(21), decreased apoptotic activity (21), and extensive cellular
proliferation (12,22) in the atherosclerotic lesions. Retino-
blastoma gene, the first tumor suppressor gene identified
molecularly, also plays a pivotal role in regulating cell
proliferation. In fact, introduction of the Rb gene via an
adenovirus vector has been shown to inhibit vascular smooth
muscle cell proliferation (23). One animal study showed
retinoblastoma gene–deleted mice had enhanced athero-
sclerosis development, involving increases in atherosclerotic
*(Standard Error) p Value Adjusted Means†
Reference 115.2
0.92 (0.74) 0.214 116.2
0.62 (0.75) 0.404 115.9
Reference 68.7
0.95 (0.55) 0.084 69.7
0.34 (0.55) 0.539 68.4
Reference 95.0
0.56 (0.81) 0.494 95.5
0.53 (0.82) 0.513 95.5
Reference 92.9
1.43 (1.31) 0.275 91.4
1.12 (1.32) 0.396 91.7
Reference 131.4
5.50 (7.93) 0.488 125.9
2.04 (8.01) 0.799 129.4
Reference 60.2
0.42 (0.85) 0.617 59.8
0.09 (0.85) 0.912 60.2
Reference 0.054
0.05 (0.14) 0.729 0.006
0.02 (0.14) 0.898 0.036
coefficients can be interpreted as differences in various metabolic risks comparing women with
age, race, health behaviors (smoking and alcohol consumption), and sex behavior.lesion area and increases in smooth muscle cell area (24).
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pressor gene products (p53 and pRb) and may therefore
accelerate the atherosclerotic process.
Our study has several implications and also raises a
number of important questions for future research. In
addition to being a causative pathogen for cervical cancer,
HPV appears to have roles in the management and preven-
tion of CVD among women. Detecting the presence of a
HPV infection may be useful in identifying and targeting
women at risk for subsequent CVD who may require
additional attention to avoid the development of cardiovas-
cular events. Second, our findings may serve as a theoretical
basis for additional benefit in cardiovascular health with
HPV vaccination for women. Bivalent HPV vaccine
(HPV2, Cervarix), directed against 2 oncogenic types, HPV
16 and 18, and quadrivalent HPV vaccine (HPV4, Garda-
sil), directed against 2 oncogenic types, HPV 16 and 18, as
well as 2 nononcogenic types, HPV 6 and 11, are the current
vaccines to prevent HPV infection and related STDs and
tumors. Although HPV 16 and 18 are the only 2 cancer-
associated oncogenic vaccine types, efficacy of vaccines for
protection against cervical lesions due to other nonvaccine
oncogenic types (HPV 31, 33, 35, 39, 45 51, 52, 56, 58, 59,
66, and 68) was demonstrated and estimated to be 37.4%
(25). Therefore, HPV vaccination may have potential car-
diovascular benefits and could have public health implica-
tions. Third, our analysis indicates that infection with
cancer-associated HPVs (HPV 16, 18, and nonvaccine
oncogenic types) has a strong association with CVD. Data
from the previous randomized controlled clinical trials
(26,27) of HPV vaccines could be reassessed for cardiovas-
cular endpoints. A clinical study prospectively testing
whether HPV immunization positively modifies the cardio-
vascular outcomes in women may be warranted. An impor-
tant step towards reducing the disabling impact of CVD is
early identification of (and potential interventions for)
potential risk factors. Examining these questions may pro-
vide evidence of potentially modifiable factors in the setting
Association Between Cardiovascular Disease and HPVTable 3 Association Between Cardiovascular Disease and HPV
Model 1 Model 2
OR (95% CI) p Value OR (95% CI) p Va
Presence of HPV DNA
Negative (reference) 1.0 1.0
Positive 2.46 (1.42–4.27) 0.001 2.13 (1.21–3.74) 0.00
HPV genotypes
Negative HPV (reference) 1.0 1.0
Other HPV types 2.13 (1.12–4.06) 0.021 1.91 (0.99–3.69) 0.05
Cancer-associated
HPV types
2.87 (1.52–5.43) 0.001 2.39 (1.24–4.61) 0.00
Adjusted covariates: Model 1  Age and race. Model 2  Model 1  health behaviors (smoking a
iver disease, thyroid disease, estimated glomerular filtration rate, sexually transmitted disease, hi
anagement (hypertension, diabetes mellitus, waist circumference, triglycerides, high-density ipop
f antihypertensive agents or cholesterol-lowering medications). Model 5Model 3metabolic z-s
apillomavirus) types  HPV types 16, 18, 31, 33, 35, 39, 45 51, 52, 56, 58, 59, and 68.
CI  confidence interval; OR  odds ratio.of CVD prevention. Last, studies for the interaction be-tween HPV oncoproteins and p53/pRb has been mostly
confined to HPV types 16 and 18; data from other onco-
genic HPV types were sparse (28,29) and are warranted for
better understanding of the molecular pathway from HPV
infection to atherosclerosis.
Study limitations. The study is cross-sectional, and a
causal relationship of HPV infection in the development of
cardiovascular events cannot be established and should be
further explored. A follow-up study with collection of
cardiovascular outcomes in relation to status of HPV infec-
tion is required. Second, our analysis was limited to women.
The association between HPV and CVD is still unknown
among men. Third, although evidence has shown a high
correlation of HPV DNA detection in self-collected swabs
compared with swabs collected by healthcare professionals
(30,31), self-collected cervicovaginal samples, to some ex-
tent, may still suffer from under-recognizing HPV infec-
tion, thus potentially underestimating the association. Last,
determination of cardiovascular events or illness is from
self-reporting in the NHANES and may not be able to fully
reflect CVD and may suffer from recall bias or misclassifi-
cation. A proper follow-up with objective confirmation of
cardiovascular outcomes is essential. Although the agree-
ment between self-reported cardiovascular endpoints (in-
cluding myocardial infarction, stroke, pulmonary embolism,
and venous thrombosis) with review by study physicians at
clinical centers was substantial according to a recent study
from the Women’s Health Initiatives Study (32), the
association between HPV infection and cardiovascular out-
come would be more consolidated if cardiovascular variables
could be obtained more objectively in the future. Taken
together, our findings are hypothesis generating, and the
results bring to light several important research questions
(such as prospective data collection of objective cardiovas-
cular outcomes in relation to HPV infection, examination of
cardiovascular effects from HPV vaccination in existing
vaccine trials, or even assessment of atherosclerosis in
papillomavirus animal models) that deserve further
Model 3 Model 4 Model 5
OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
1.0 1.0 1.0
.14 (1.21–3.79) 0.009 2.30 (1.27–4.16) 0.006 2.06 (1.14–3.74) 0.017
1.0 1.0 1.0
.88 (0.97–3.67) 0.063 1.89 (0.94–3.78) 0.072 1.70 (0.84–3.43) 0.137
.46 (1.27–4.77) 0.008 2.86 (1.43–5.70) 0.003 2.53 (1.27–5.01) 0.008
hol consumption) and sex behavior. Model 3  Model 2  medical comorbidities (lung disease,
cervical cancer, history of all other cancer). Model 4  Model 3  cardiovascular risk factors and
holesterol, log-transformed levels of C-reactive protein and urinary albumin-to-creatinine ratio, use
se of antihypertensive agents or cholesterol-lowering medications. Cancer-associated HPV (humanlue
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HPV infection, especially cancer-associated oncogenic
types, is likely associated with myocardial infarction or
stroke among women. The association cannot be explained
by coexisting medical conditions, cardiovascular risk factors,
metabolic burden, and their management. We provided new
information and possible implications on the associations
between HPV infection and cardiovascular events among
women in the United States where data currently do not
exist.
Reprint requests and correspondence: Dr. Hsu-Ko Kuo, Uni-
versity of Texas Medical Branch, 301 University Boulevard,
Galveston, Texas 77555. E-mail: hskuo@utmb.edu.
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